评估针对 HPV+ 宫颈癌或口咽癌的 Lenti-HPV-07 免疫疗法的研究
一项开放标签 1/2a 期临床试验,旨在评估基于慢病毒载体的人乳头瘤病毒 (Lenti-HPV-07) 治疗疫苗在 HPV 相关口咽鳞状细胞癌或宫颈癌
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
The main questions aim to answer are:
- Is Lenti-HPV-07 safe?
- Does Lenti-HPV-07 induce an immune response?
Participants will be assigned to a group based on their cancer type
- either study drug group A: recurrent and/or metastatic cancer
- or study drug group B: newly diagnosed with locally advanced cancer
After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.
研究概览
地位
详细说明
As of 06Nov2025 the recruitment in ARm A of the study (recurrent/metastatic cancers) has been closed to further enrollment, in accordance with the protocol and the study's prespecified operational and/or scientific considerations. No new participants will be enrolled into Arm A, and no additional study drug will be administered within this arm.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Anastasia DEMIDOV
- 电话号码:(0)614515520 +33
- 邮箱:ademidova@theravectys.com
学习地点
-
-
Florida
-
Orlando、Florida、美国、32827
- 招聘中
- Florida Cancer Specialists (from Sarah Canon research Institute)
-
首席研究员:
- Cesar Augusto Perez Batista, MD
-
Tampa、Florida、美国、33606
- 招聘中
- Tampa General Hospital
-
首席研究员:
- Noman Ashraf, MD
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
首席研究员:
- Guilherme Rabinowits, MD
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74146
- 招聘中
- Oklahoma Cancer Specialists and Research Institute, LLC
-
首席研究员:
- Daron Street, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
- ECOG performance status of 0 or 1
- adequate hepatic, renal, pulmonary, and bone marrow/hematological function
Exclusion Criteria:
- with seropositivity for HIV, active hepatitis C virus (HCV) infection, or hepatitis B (HBV) infection
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A : Refractory newly diagnosed
Refractory recurrent and/or metastatic cervical or oropharyngeal cancer that is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy). |
two Lenti-HPV-07 intramuscular injections one month apart |
|
实验性的:Arm B : newly diagnosed locally advanced
Participants who have newly diagnosed locally advanced HPV-related oropharyngeal cancer (defined by AJCC 8th edition [ie, T1-2N2-N3, T3-T4N0-N3]) or cervical cancer (stages IB to IVA) that has never been treated with curative intent, and who are candidates to begin an SoC treatment (surgery, radiation therapy with or without chemotherapy). |
a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability
大体时间:12 months after last injection
|
Frequency, intensity, and relationship of adverse events with vaccine administration per CTCAE v5.0 |
12 months after last injection
|
|
OBD
大体时间:28 days after last injection
|
To identify the optimal biological dose (OBD) and schedule for subsequent trials of Lenti-HPV-07 |
28 days after last injection
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Immunogenicity
大体时间:12 months after last injection
|
|
12 months after last injection
|
|
PD-L1 expression
大体时间:12 months after last injection
|
PD-L1 tumor expression, as measured by composite positive score, by 50% both pre- and post-injection |
12 months after last injection
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Lenti-HPV-07-CT01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.